Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing both insulin and dasiglucagon. The company's pipeline includes Dasiglucagon that is in Phase III clinical trials for congenital hyperinsulinism. The company is also developing glepaglutide, a long acting GLP-2 analog, which is in Phase III clinical trials for the treatment of short bowel syndrome. Zealand Pharma A/S has collaboration agreements with Sanofi-Aventis Deutschland GmbH; Boehringer Ingelheim International GmbH; Alexion Pharmaceuticals, Inc.; and Beta Bionics, Inc. The company was incorporated in 1998 and is headquartered in Copenhagen, Denmark.
Earnings for Zealand Pharma A/S (ZEAL.CO)
Earnings in 2023 (TTM): $-103,300,376
According to Zealand Pharma A/S's latest financial reports the company's current earnings (TTM) are $-103,300,376. The earnings displayed on this page is the company's Pretax Income.
Earnings history of Zealand Pharma A/S
Annual Earnings
| Year | Income Before Tax | Net Income |
|---|---|---|
| 2023 | $-103,300,376 | $-102,553,382 |
| 2022 | $-141,652,078 | $-140,714,911 |
| 2021 | $-149,652,314 | $-148,371,233 |
| 2020 | $-122,359,646 | $-123,390,806 |
| 2019 | $-84,037,088 | $-83,288,637 |
| 2018 | $91.09 M | $84.71 M |
| 2017 | $-40,478,580 | $-39,677,085 |
| 2016 | $-23,230,252 | $-22,428,757 |
| 2015 | $-17,462,691 | $-16,606,548 |
| 2014 | $-10,563,710 | $-9,470,762 |
| 2013 | $-26,766,450 | $-26,778,254 |
| 2012 | $5.3 M | $5.3 M |
| 2011 | $1.95 M | $992.83 K |
| 2010 | $-15,247,941 | $-15,247,941 |
| 2009 | $-11,032,949 | $-11,662,342 |
| 2008 | $-4,915,644 | $-4,915,644 |
| 2007 | $-8,014,954 | $-8,014,954 |